Pantarhei Bioscience has sold in Estetra, its oral contraceptive development JV, to partner Uteron Pharma and will use the proceeds to fund further development.
Biopharmaceutical CMOs have seen their business slowly shrink as companies seek less volume and smaller batches, but outsourcing is expected to increase over the next three years.
West Pharmaceuticals says it is still intent on shifting to proprietary products following results from its packaging and contract manufacturing businesses.
The US FDA says draft guidelines on risk-based immunogenicity testing of protein drugs will encourage the pharma industry to continue development efforts.
CMO ProBioGen says its GlymaxX ADCC antibody enhancement technology can be adapted to any biomanufacturing cell line and will attract both Big and Small Pharma.
Quintiles painted a rosy picture of the CRO sector in its much anticipated IPO, predicting that biopharma R&D spending will increase and demand for outsourced research will grow.
PPD has expanded its central lab testing services at its Brussels and Singapore labs and will offer additional services in microbiology, peripheral blood mononuclear cell and molecular pathology services.
Protalix Biotherapeutics is attempting to use its US FDA-approved Gaucher's disease treatment as a proof of concept and springboard for its plant-based cell manufacturing technology.
EpiVax says combining its immune 'off switch’ drugs with Novozymes’ half-life boosting Albufuse platform could deliver a $3bn (€2.2bn) section of the autoimmune disease market.
in-Pharmatechnologist.com presents a roundup of news in the fine chemicals sector, beginning with Johnson Matthey which has started a review of its active pharmaceutical ingredient (API) business after competition in the UK impacted its third quarter...
Teva says the offloading of its Californian manufacturing facility is part of cost-cutting plans designed to save $2bn (€1.5bn). in the next few years.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Recipharm, Aesica and SMS Oncology.
With Angiomax potentially going generic in 2015, The Medicines Company has collaborated with Alnylam over a 'pragmatic' high cholesterol drug to aid future growth.
Highly sought-after guidance on quality agreements for contract manufacturing organizations (CMOs) and biosimilar developers is expected in 2013, according to a list of future guidance documents released by the US Food and Drug Administration (FDA).
European drugmakers are seeking between six months and a year to prepare and print updated product information, including the black symbol for drugs that require additional monitoring as part of their approval.
Following a wave of recent investment in ADC production, Synthon has opened an ADC manufacturing facility in Nijmegen, Netherlands, to help bring its first preclinical ADC program to clinical trials by 2014.
The UK's cell therapy industry now has a database of all ongoing clinical trials in the country with the aim of expanding research partnerships and pushing more early-stage trials to later stages.
The Singapore Economic Development Board (SEDB) says it wants to nurture industry, academic and institutional alliances to attract further global investment in ‘Asia’s fastest growing bio-cluster.’
ADC Biotechnology has secured funding to take its cost-cutting antibody drug conjugate (ADC) tech to market and says pharma demand will drive partnerships and maybe even attract CMO takeover bids.
Merck Millipore hopes the promise of reducing the number of experiments needed during process development will win customers for its new MAb development kit.
Showa Denko KK (SDK) wants a share of the of the biopharmaceutical resins sector and has partnered with purification tech firm BIA Separations (BIASep) to get it.
GE Healthcare says new cell science lab in Wales will save drugmakers time and money and create more accurate alternatives to animal-based drug toxicity testing models.
India's national Atomic Energy Regulation Board (AERB) has approved GVK Biosciences to perform certain isotope-labeling research in its facility, according to the Hyderabad-based contract research organization (CRO).
